{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:29Z","timestamp":1740126809394,"version":"3.37.3"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Viele Systemtherapien, die in der Behandlung uroonkologischer Erkrankungen eingesetzt\n      werden, verursachen St\u00f6rungen der H\u00e4matopoese. Dadurch kann es zum Auftreten einer Neutropenie\n      kommen. Neutropene Patienten sind gegen\u00fcber bakteriellen, aber auch anderen Infektionen\n      anf\u00e4llig, h\u00e4ufig ist Fieber bei diesen Patienten das einzige Symptom. Eine solches neutropenes\n      Fieber bedeutet in aller Regel nicht nur eine lebensbedrohliche Therapiekomplikation mit einer\n      oft deutlichen Einschr\u00e4nkung der Lebensqualit\u00e4t der Patienten, sondern kann durch\n      Therapieverz\u00f6gerungen oder erforderliche Dosismodifikationen auch die Prognose verschlechtert.\n      Granulozyten-Kolonie-stimulierende Faktoren (GCSF), die eine vermehrte Bildung von\n      neutrophilen Granulozyten stimulieren, k\u00f6nnen sowohl zur unterst\u00fctzenden Behandlung bei der\n      febrilen Neutropenie als auch zu deren Prophylaxe eingesetzt werden. Dabei ist die korrekte\n      Indikationsstellung f\u00fcr eine solche GCSF-Unterst\u00fctzung sowohl vom generellen Risiko einer\n      febrilen Neutropenie, der jeweils eingesetzten Therapie, als auch von individuellen\n      Patientenfaktoren und dem Therapieziel (palliative vs. kurative Therapie) abh\u00e4ngig. Basierend\n      auf den aktuellen Empfehlungen der deutschen sowie internationalen Leitlinien m\u00f6chte dieser\n      Beitrag einen aktuellen und praxisorientierten \u00dcberblick zum Einsatz von GCSF in der\n      Uroonkologie geben. <\/jats:p>","DOI":"10.1055\/a-2128-4965","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T23:07:10Z","timestamp":1692745630000},"page":"38-43","source":"Crossref","is-referenced-by-count":0,"title":["Neutropenie \u2013 wann ist eine GCSF Unterst\u00fctzung notwendig?"],"prefix":"10.1055","volume":"55","author":[{"given":"Marc","family":"Rehlinghaus","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Centrum f\u00fcr Integrierte Onkologie (CIO) D\u00fcsseldorf, CIO Aachen Bonn K\u00f6ln D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Rehker","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Centrum f\u00fcr Integrierte Onkologie (CIO) D\u00fcsseldorf, CIO Aachen Bonn K\u00f6ln D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Centrum f\u00fcr Integrierte Onkologie (CIO) D\u00fcsseldorf, CIO Aachen Bonn K\u00f6ln D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla Marisa","family":"Grunewald","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Centrum f\u00fcr Integrierte Onkologie (CIO) D\u00fcsseldorf, CIO Aachen Bonn K\u00f6ln D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-8691","authenticated-orcid":false,"given":"G\u00fcnter","family":"Niegisch","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Centrum f\u00fcr Integrierte Onkologie (CIO) D\u00fcsseldorf, CIO Aachen Bonn K\u00f6ln D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"C Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"T Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"ST Tagawa","year":"2021","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal Management of Neutropenic Fever in Patients With Cancer","volume":"15","author":"AJ Zimmer","year":"2019","journal-title":"J Oncol Pract"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"J Klastersky","year":"2000","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00062752-200205000-00002","article-title":"Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor","volume":"9","author":"J Thomas","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"J Klastersky","year":"2016","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ESMO"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update","volume":"36","author":"RA Taplitz","year":"2018","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/annonc\/mdv389","article-title":"A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN","volume":"26","author":"RC Leonard","year":"2015","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ESMO"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1056\/NEJM199706193362502","article-title":"Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia","volume":"336","author":"LC Hartmann","year":"1997","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","article-title":"The five \"Ws\" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)","volume":"89","author":"M Lambertini","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"103193","DOI":"10.1016\/j.critrevonc.2020.103193","article-title":"Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review","volume":"157","author":"P Lapidari","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","article-title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","volume":"29","author":"GH Lyman","year":"2018","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ESMO"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"109227","DOI":"10.1016\/j.intimp.2022.109227","article-title":"The effect of concomitant use of Colony-Stimulating factors on bleomycin pulmonary toxicity \u2013 A systematic review and meta-analysis","volume":"112","author":"S Mahdi Seyedzadeh Sani","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/1097-0142(19900901)66:5<857::aid-cncr2820660508>3.0.co;2-g","article-title":"The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients","volume":"66","author":"RJ Motzer","year":"1990","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"CD003039","DOI":"10.1002\/14651858.CD003039.pub2","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia","volume":"2014","author":"R Mhaskar","year":"2014","journal-title":"The Cochrane database of systematic reviews"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00520-013-1758-y","article-title":"The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients","volume":"21","author":"J Klastersky","year":"2013","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s12325-018-0798-6","article-title":"Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia","volume":"35","author":"P Cornes","year":"2018","journal-title":"Adv Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155215625459","article-title":"Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review","volume":"22","author":"S Mitchell","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1472-6963-14-189","article-title":"Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis","volume":"14","author":"D Weycker","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s00520-017-3703-y","article-title":"The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review","volume":"25","author":"GH Lyman","year":"2017","journal-title":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/03007995.2017.1386858","article-title":"Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015","volume":"33","author":"D Weycker","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00520-017-3842-1","article-title":"Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations","volume":"25","author":"M Aapro","year":"2017","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2128-4965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:52:39Z","timestamp":1730825559000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2128-4965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":23,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,2,8]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2128-4965","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"type":"print","value":"0001-7868"},{"type":"electronic","value":"1438-8820"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}